Cargando…

Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins

More than one and half years have passed, as of August 2021, since the COVID-19 caused by the novel coronavirus named SARS-CoV-2 emerged in 2019. While the recent success of vaccine developments likely reduces the severe cases, there is still a strong requirement of safety and effective therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hijikata, Atsushi, Shionyu, Clara, Nakae, Setsu, Shionyu, Masafumi, Ota, Motonori, Kanaya, Shigehiko, Shirai, Tsuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Biophysical Society of Japan 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550875/ https://www.ncbi.nlm.nih.gov/pubmed/34745807 http://dx.doi.org/10.2142/biophysico.bppb-v18.025

Ejemplares similares

Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2
por: Hijikata, Atsushi, et al.
Publicado: (2021)

Decoding disease-causing mechanisms of missense mutations from supramolecular structures
por: Hijikata, Atsushi, et al.
Publicado: (2017)

Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence
por: Lestari, Beni, et al.
Publicado: (2019)

The Role of the Prod1 Membrane Anchor in Newt Limb Regeneration
por: Nomura, Kaoru, et al.
Publicado: (2016)

Curcumin Derivatives Verify the Essentiality of ROS Upregulation in Tumor Suppression
por: Nakamae, Ikuko, et al.
Publicado: (2019)

AS-EAST: a functional annotation tool for putative proteins encoded by alternatively spliced transcripts
por: Shionyu, Masafumi, et al.
Publicado: (2012)

RESOPS: A Database for Analyzing the Correspondence of RNA Editing Sites to Protein Three-Dimensional Structures
por: Yura, Kei, et al.
Publicado: (2009)

AS-ALPS: a database for analyzing the effects of alternative splicing on protein structure, interaction and network in human and mouse
por: Shionyu, Masafumi, et al.
Publicado: (2009)

Repurposing current therapeutic regimens against SARS-CoV-2 (Review)
por: K. Konstantinidou, Sofia, et al.
Publicado: (2020)

Role of a bacterial glycolipid in Sec-independent membrane protein insertion
por: Nomura, Kaoru, et al.
Publicado: (2022)

Single-particle analysis of full-length human poly(ADP-ribose) polymerase 1
por: Kouyama, Kenichi, et al.
Publicado: (2019)

Common and unique strategies of myoglobin evolution for deep-sea adaptation of diving mammals
por: Isogai, Yasuhiro, et al.
Publicado: (2021)

Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2
por: Yan, Haiyan, et al.
Publicado: (2021)

Anti-HIV drug repurposing against SARS-CoV-2
por: Sang, Peng, et al.
Publicado: (2020)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Tracing whale myoglobin evolution by resurrecting ancient proteins
por: Isogai, Yasuhiro, et al.
Publicado: (2018)

Computational guided approach for drug repurposing against SARS-CoV-2
por: Anand, Jigisha, et al.
Publicado: (2021)

Drug repurposing against SARS-CoV-2 using computational approaches
por: Kumar, Sumit, et al.
Publicado: (2022)

Computational repurposing of tamibarotene against triple mutant variant of SARS-CoV-2
por: Mujwar, Somdutt
Publicado: (2021)

What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?
por: Martinez, Miguel Angel
Publicado: (2022)

Current status of therapeutic monoclonal antibodies against SARS-CoV-2
por: Kumar, Sanjeev, et al.
Publicado: (2021)

Current Status of Baricitinib as a Repurposed Therapy for COVID-19
por: Saber-Ayad, Maha, et al.
Publicado: (2021)

A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
por: Simonis, Alexander, et al.
Publicado: (2020)

Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target
por: DURDAĞI, Serdar
Publicado: (2020)

Molecular targets and system biology approaches for drug repurposing against SARS-CoV-2
por: Singh, Rahul Kunwar, et al.
Publicado: (2020)

Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2
por: Niranjan, Vidya, et al.
Publicado: (2022)

Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2
por: Parashar, Nidarshana Chaturvedi, et al.
Publicado: (2020)

Correction: Current status of therapeutic monoclonal antibodies against SARS-CoV-2
por: Kumar, Sanjeev, et al.
Publicado: (2022)

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
por: Pizzorno, Andrés, et al.
Publicado: (2020)

Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2
por: Eweas, Ahmad F., et al.
Publicado: (2021)

Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection
por: Vohra, Manik, et al.
Publicado: (2021)

Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies
por: Mahmoud, Amal, et al.
Publicado: (2021)

Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity
por: Kamat, Siya, et al.
Publicado: (2021)

Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2
por: Tammam, Salma N., et al.
Publicado: (2021)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Correction to: Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2
por: Niranjan, Vidya, et al.
Publicado: (2022)

In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach
por: Zapata-Cardona, Maria I., et al.
Publicado: (2023)

Clinical Trials of Repurposed Antivirals for SARS-CoV-2
por: Martinez, Miguel Angel
Publicado: (2020)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ljoode520e9g41dmuenskp063v